공시 • May 08
AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026 AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026 공시 • Mar 26
Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis Patients Vasomune Therapeutics, Inc. and AnGes, Inc. have treated the first patient in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc., and AnGes, Inc., will work to stabilize the cerebral vasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. Pegevongitide (AV-001) offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels and prevent vascular leakage. With the initiation of this study, Vasomune now moves into a new and exciting arena of working to improve cerebrovascular health in patients. Positive findings from this study will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population. 공시 • Feb 10
AnGes, Inc., Annual General Meeting, Mar 27, 2026 AnGes, Inc., Annual General Meeting, Mar 27, 2026. 공시 • Dec 03
AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026 AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026 공시 • Sep 04
Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients A groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. The clinical study is led by Dr. Christopher McIntyre, Professor of Medicine, Medical Biophysics, and Paediatrics at Western University and holder of the Robert Lindsay Chair of Dialysis Research and Innovation. Dr. McIntyre also serves as Director of the Lilibeth Caberto Kidney Clinical Research Unit at London Health Sciences Centre, where he practices as a Clinical Nephrologist. A recognized leader in kidney research, Dr. McIntyre leads a multidisciplinary team investigating the pathophysiological impact of chronic kidney disease on cardiovascular, neurological, hepatic, and gastrointestinal systems. His research integrates multimodal imaging with clinical and translational studies to develop and evaluate novel therapeutic strategies. His recent work increasingly focuses on mitigating the adverse consequences of dialysis therapy itself, and he has recently published about dialysis and cognitive impairment in Nature Reviews Nephrology. Patients, particularly those over 55, face a high burden of moderate-to-severe cognitive impairment, affecting up to 70% of this age group. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. "Pegevongitide ("AV-001") offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels, prevent vascular leakage and reduce vascular inflammation. With this approval from Health Canada and the initiation of this study, Vasomune now moves into a new and exciting opportunity to improve cerebrovascular health in patients," according to Dr. Harold Kim, Vice-President of Research at Vasomune Therapeutics Inc. Published data using Pegevongitide(AV-001) demonstrated that this mechanism can improve neurological health, reduce cognitive impairment, and reduce cerebrovascular leak. The study will assess whether Pegevong it can reduce hemodialysis-induced cytotoxic brain edema and preserve white matter integrity. Advanced neuroimaging techniques, cognitive assessments, and blood biomarkers will be used to evaluate outcomes. Supported by a prestigious Heart and Stroke Foundation grant, this research has the potential to redefine how brain health is protected in hemodialysis patients. Positive findings will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population. 공시 • Sep 01
AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025 AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025 